Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited (ASX:IMU) for $6 million on April 16, 2024. Imugene will also transfer process and analytical development of Azer-cel to Kincell in order to support process and method optimization for commercial readiness.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.087 AUD | +6.10% | +2.35% | -20.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.91% | 394M | |
+1.77% | 42.86B | |
+46.28% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.